1. Copyright © 2012 American Medical Association. All rights reserved.
From: Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With StatinsA Meta-analysis
JAMA. 2012;307(12): doi: /jama
Figure Legend:
Data markers indicate hazard ratios for risk of major cardiovascular events per 1-SD increase of the lipid or apolipoprotein and 95% CIs. Dashed line indicates point estimate for all participants combined. All interaction terms were by presence or absence of the listed characteristics and were nonsignificant. BMI indicates body mass index; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and TG, triglyceride.
Date of download: 3/9/2018
Copyright © 2012 American Medical Association. All rights reserved.

2. Copyright © 2012 American Medical Association. All rights reserved.
From: Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With StatinsA Meta-analysis
JAMA. 2012;307(12): doi: /jama
Figure Legend:
Data markers indicate hazard ratios (HRs) for risk of major cardiovascular events per 1-SD increase of on-statin low-density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (non–HDL-C), or apolipoprotein B (apoB) and 95% CIs. For placebo-controlled trials, data from the placebo group were not used in this analysis. Dashed line indicates point estimate for all participants combined. All interaction terms by study were nonsignificant.
Date of download: 3/9/2018
Copyright © 2012 American Medical Association. All rights reserved.

3. Copyright © 2012 American Medical Association. All rights reserved.
From: Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With StatinsA Meta-analysis
JAMA. 2012;307(12): doi: /jama
Figure Legend:
Data markers indicate hazard ratios (HRs) and 95% CIs for risk of major cardiovascular events. Results are shown for 4 categories of statin-treated patients based on whether or not they reached the low-density lipoprotein cholesterol (LDL-C) target of 100 mg/dL and the non–high-density lipoprotein cholesterol (non–HDL-C) target of 130 mg/dL. HRs were adjusted for sex, age, smoking, diabetes, systolic blood pressure, and trial.
Date of download: 3/9/2018
Copyright © 2012 American Medical Association. All rights reserved.